Recipharm Stockholm Competitors and Similar CompaniesClear all

Recipharm Stockholm's competitors and similar companies include Antibiotice, Eagle Veterinary Technology, Vetoquinol and Laboratorio Proagro.

	Recipharm Stockholm Recipharm Stockholm is a manufacturer and developer of drugs in pharmaceuticals for human and veterinary use.	Antibiotice Antibiotice is a pharmaceutical company.	Eagle Veterinary Technology Eagle Veterinary Technology (formerly known as Eagle Chemical) is a company that manufactures, develops, and sells animal healthcare products.	Vetoquinol Vetoquinol is a veterinary pharmaceutical company.	Laboratorio Proagro Laboratorio Proagro is a laboratory of veterinary drugs for large and small animals.
Founding Date	Founding Date 2004	Founding Date 1955	Founding Date 1970	Founding Date 1993	Founding Date N/A
Type	Type Subsidiary	Type Private	Type Public	Type Private	Type Private
Tags	Tags Healthcare drug development pharmacy veterinary	Tags Healthcare drug development pharmacy veterinary	Tags Healthcare distribution drug development pets pharmacy veterinary	Tags Healthcare drug development pharmacy veterinary	Tags Healthcare drug development pharmacy veterinary
Locations	Locations Älvsjö, SE HQ	Locations Iași, RO HQ Chișinău, MD Bucharest, RO Sremska Kamenica, RS Kyiv, UA	Locations Yesan-gun, KR HQ Seoul, KR	Locations Brisbane Airport, AU HQ Lavaltrie, CA Magny Vernois, FR Ismaning, DE Mumbai, IN Panighina, IT see more	Locations Rosario, AR HQ
Employees	Employees 134	Employees 601	Employees N/A	Employees 781% decrease	Employees 647% increase
Financial
Revenue (est.)	Revenue (est.) kr219.5m (FY, 2020)	Revenue (est.) N/A	Revenue (est.) ₩41.7b (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods kr145.8m (FY, 2020)	Cost of goods N/A	Cost of goods ₩27b (FY, 2024)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit kr73.8m (FY, 2020)	Gross profit N/A	Gross profit ₩14.8b (FY, 2024)	Gross profit N/A	Gross profit N/A
Net income	Net income (kr864.4k) (FY, 2020)	Net income N/A	Net income ₩3.7b (FY, 2024)	Net income N/A	Net income N/A